Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) is a clinical-stage biopharmaceutical company dedicated to advancing novel treatments for cancer and obesity. Founded in 2009 and headquartered in Norwood, Massachusetts, the company has a mission to help people defeat serious illness through cutting-edge research and compassionate care. Business and Pipeline: Corbus focuses ...Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) is a clinical-stage biopharmaceutical company dedicated to advancing novel treatments for cancer and obesity. Founded in 2009 and headquartered in Norwood, Massachusetts, the company has a mission to help people defeat serious illness through cutting-edge research and compassionate care.
Business and Pipeline: Corbus focuses on developing precision medicines for oncology and obesity. Its lead product candidate, CRB-701, is an antibody-drug conjugate (ADC) that targets Nectin-4, a protein overexpressed on cancer cells, to deliver a cytotoxic payload directly to tumors. CRB-601 is an anti-integrin monoclonal antibody designed to block the activation of TGFβ, a key immunosuppressive factor in the tumor microenvironment. For obesity, CRB-913 is a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist that aims to reduce appetite and promote weight loss with minimized central nervous system side effects.
Clinical and Regulatory Status: As a clinical-stage company, Corbus has no approved products and does not generate revenue from product sales. The company's activities are primarily research and development, leading to significant operating losses. Financial metrics from the trailing twelve months (TTM) indicate a negative EBITDA, negative free cash flow, and a high burn rate, characteristic of early-stage biotech firms. The company's cash position is modest, with working capital of approximately $101 million, and it will require additional capital to fund ongoing trials.
Financial Overview: Despite financial losses, Corbus has a relatively strong balance sheet with no debt and ample liquidity for near-term operations. The market capitalization is around $176 million, and the stock price has ranged from $7.12 to $20.56 over the past 52 weeks. Key financial ratios indicate the company is unprofitable, with a negative return on equity and assets. However, the company has managed to keep research and development spending efficient.
Leadership and Employees: The CEO, Yuval Cohen, Ph.D., has served since 2014 and co-founded the company. The leadership team includes experts in oncology and drug development. The company has approximately 36 full-time employees, though LinkedIn reports a range of 51-200. The small size allows for agile decision-making and a focused approach to development.
Future Outlook: Corbus is positioned to address significant unmet medical needs. If its pipeline candidates succeed in clinical trials, the company could offer substantial value to patients and investors. However, the inherent risks of drug development, including regulatory hurdles and clinical trial failures, remain. The company's success will depend on the outcomes of ongoing trials and its ability to secure partnerships or funding.
